Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Position Raised by Ashton Thomas Securities LLC

Ashton Thomas Securities LLC raised its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 2.5% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 810 shares of the biopharmaceutical company’s stock after purchasing an additional 20 shares during the quarter. Ashton Thomas Securities LLC’s holdings in Regeneron Pharmaceuticals were worth $577,000 as of its most recent SEC filing.

Several other hedge funds also recently modified their holdings of the company. FSA Wealth Management LLC acquired a new position in Regeneron Pharmaceuticals during the third quarter worth about $26,000. OFI Invest Asset Management acquired a new position in shares of Regeneron Pharmaceuticals in the 4th quarter worth approximately $28,000. Rakuten Securities Inc. raised its holdings in shares of Regeneron Pharmaceuticals by 62.5% in the 4th quarter. Rakuten Securities Inc. now owns 39 shares of the biopharmaceutical company’s stock worth $28,000 after purchasing an additional 15 shares in the last quarter. Avalon Trust Co acquired a new stake in Regeneron Pharmaceuticals during the fourth quarter valued at approximately $36,000. Finally, Crowley Wealth Management Inc. bought a new stake in Regeneron Pharmaceuticals during the fourth quarter worth approximately $36,000. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals Stock Performance

Shares of REGN opened at $634.14 on Wednesday. The company has a quick ratio of 3.95, a current ratio of 4.73 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals, Inc. has a 12 month low of $633.10 and a 12 month high of $1,211.20. The company’s fifty day moving average is $687.18 and its 200-day moving average is $806.20. The firm has a market cap of $69.33 billion, a price-to-earnings ratio of 16.57, a price-to-earnings-growth ratio of 2.34 and a beta of 0.27.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share (EPS) for the quarter, topping the consensus estimate of $11.21 by $0.86. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The company had revenue of $3.79 billion during the quarter, compared to the consensus estimate of $3.76 billion. During the same quarter in the prior year, the company posted $11.86 EPS. The firm’s revenue was up 10.3% on a year-over-year basis. Equities analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Thursday, March 20th. Stockholders of record on Thursday, February 20th were given a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.56%. The ex-dividend date was Thursday, February 20th. Regeneron Pharmaceuticals’s dividend payout ratio is 2.30%.

Wall Street Analyst Weigh In

REGN has been the topic of several research reports. Leerink Partners raised Regeneron Pharmaceuticals from a “market perform” rating to an “outperform” rating and upped their price target for the company from $762.00 to $834.00 in a report on Wednesday, February 5th. Piper Sandler decreased their price target on Regeneron Pharmaceuticals from $1,195.00 to $1,013.00 and set an “overweight” rating for the company in a research report on Monday, January 27th. Bernstein Bank cut their price objective on Regeneron Pharmaceuticals from $1,070.00 to $1,000.00 in a report on Tuesday, February 4th. Citigroup decreased their target price on shares of Regeneron Pharmaceuticals from $795.00 to $750.00 and set a “neutral” rating for the company in a report on Tuesday, January 28th. Finally, Wells Fargo & Company cut their price target on shares of Regeneron Pharmaceuticals from $1,050.00 to $900.00 and set an “overweight” rating on the stock in a report on Friday, January 10th. One analyst has rated the stock with a sell rating, six have issued a hold rating, seventeen have assigned a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $973.13.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.